FDA
-
-
-
-
-
-
-
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
-
-
-
-
-
-
-
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
-
-
-
-
-
-
-
Syros Pharmaceuticals (SYRS) Confirms FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
-
-
-
-
-
-
-
Syros Pharmaceuticals (SYRS) Acquires Clinical-Stage Drug Candidate, SY-2101, for Acute Promyelocytic Leukemia from Orsenix, LLC
-
-
-
-
-
-
-
GBT Secures $150 Million Non-Dilutive Term Loan Financing
-
-
-
-
-
-
-
Syros Announces Appointment of Alice T. Shaw to its Board of Directors
-
-
-
-
-
-
-
Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

